Four-Year Outcomes by Donor Type from the Long-Term Extension of the Belatacept BENEFIT and BENEFIT-EXT Studies

被引：0
|
作者：
Durrbach, A. [1 ]
Medina Pestana, J. [2 ]
Becker, T. [3 ]
Grinyo, J. [4 ]
Lang, P. [5 ]
Garcia, V. D. [6 ]
Agarwal, M. [7 ]
Duan, T. [7 ]
Florman, S. [8 ]
机构：
[1] Hop Kremlin Bicetre, Paris, France
[2] Hosp Rim & Hipertensao, Sao Paulo, Brazil
[3] Hannover Med Sch, Hannover, Germany
[4] Univ Hosp Bellvitge, Barcelona, Spain
[5] Hop Henri Mondor, Creteil, France
[6] Hosp Dom Vicente Scherer, Porto Alegre, RS, Brazil
[7] Bristol Myers Squibb, Princeton, NJ USA
[8] Mt Sinai Med Ctr, New York, NY 10029 USA
来源：
TRANSPLANTATION | 2012年 / 94卷 / 10期
关键词：
D O I：
10.1097/00007890-201211271-01950
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
1312
引用
收藏
页码：987 / 987
页数：1
相关论文
共 50 条
  • [31] Outcomes as a Function of Donor Criteria from a Phase III Study of Belatacept vs Cyclosporine in Kidney Transplantation (BENEFIT-EXT).
    Florman, Sander
    Durrbach, Antoine
    Larsen, Christian
    Pestana, Jose Medina
    Vanrenterghem, Yves
    Vincenti, Flavio
    Block, Alan
    Garg, Pushkal
    Copley, J. Brian
    Xing, Jun
    Grinyo, Josep
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 150 - 150
  • [32] RENAL FUNCTION IN PATIENTS TREATED WITH BELATACEPT-OR CYCLOSPORINE-BASED REGIMENS AT YEAR 3 IN THE BENEFIT AND BENEFIT-EXT STUDIES
    Durrbach, Antoine
    Citterio, Franco
    Mulloy, Laura
    David-Neto, Elias
    Russ, Graeme
    Vitko, Sefan
    Zhang, Rubin
    Xing, Jun
    Harler, Mary Beth
    Grinyo, Josep
    TRANSPLANT INTERNATIONAL, 2011, 24 : 249 - 249
  • [33] DONOR SUB-TYPE ANALYSIS OF THREE-YEAR OUTCOMES FROM A PHASE III STUDY OF BELATACEPT IN RECIPIENTS OF EXTENDED CRITERIA DONOR KIDNEYS (BENEFIT-EXT TRIAL)
    Muehlbacher, Ferdinand
    Becker, Thomas
    Campistol, Josep M.
    Carvalho, Deise B. M.
    Florman, Sander
    Lang, Philippe
    Duan, Tao
    Agarwal, Mamta
    Larsen, Christian P.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 221 - 222
  • [34] Three-Year Outcomes From BENEFIT-EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys
    Pestana, J. O. M.
    Grinyo, J. M.
    Vanrenterghem, Y.
    Becker, T.
    Campistol, J. M.
    Florman, S.
    Garcia, V. D.
    Kamar, N.
    Lang, P.
    Manfro, R. C.
    Massari, P.
    Rial, M. D. C.
    Schnitzler, M. A.
    Vitko, S.
    Duan, T.
    Block, A.
    Harler, M. B.
    Durrbach, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (03) : 630 - 639
  • [35] Renal Function in Patients Treated with Belatacept- or Cyclosporine-Based Regimens at Year 3 in the BENEFIT and BENEFIT-EXT Studies
    Durrbach, A.
    Citterio, F.
    Mulloy, L.
    David-Neto, E.
    Russ, G.
    Vitko, S.
    Zhang, R.
    Xing, J.
    Harler, M. B.
    Grinyo, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 100 - 100
  • [36] Three-Year Outcomes in Patients with Delayed Graft Function in Phase III Studies of Belatacept Vs Cyclosporine in Kidney Transplantation (BENEFIT and BENEFIT-EXT)
    Charpentier, B.
    Vincenti, F.
    Rice, K.
    Budde, K.
    Campistol, J.
    Duan, T.
    Pupim, L.
    Florman, S.
    TRANSPLANTATION, 2012, 94 (10) : 996 - 996
  • [37] Likelihood of Improving or Maintaining Renal Function in Recipients of Extended-Criteria Donor Kidneys over Five Years with Belatacept or CsA (BENEFIT-EXT Long-Term Extension Study)
    Grinyo, J.
    Vanrenterghem, Y.
    Durrbach, A.
    Rial, M.
    Charpentier, B.
    Matas, A.
    Lehner, F.
    Pupim, L.
    Coffey, M.
    Pestana, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 310 - 310
  • [38] LONG-TERM OUTCOMES IN EPSTEIN-BARR VIRUS POSITIVE (EBV plus ) PATIENTS RECEIVING BELATACEPT (BELA) OR CYCLOSPORINE (CSA) IN BENEFIT-EXT
    Florman, S.
    Medina Pestana, J.
    Rial, M. Del C.
    Rostaing, L.
    Kuypers, D.
    Matas, A.
    Wekerle, T.
    Grinyo, J.
    Meier-Kriesche, U.
    Polinsky, M.
    Zhao, H.
    Durrbach, A.
    TRANSPLANT INTERNATIONAL, 2017, 30 : 7 - 7
  • [39] Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study
    Durrbach, A.
    Pestana, J. M.
    Florman, S.
    del Carmen Rial, M.
    Rostaing, L.
    Kuypers, D.
    Matas, A.
    Wekerle, T.
    Polinsky, M.
    Meier-Kriesche, H. U.
    Munier, S.
    Grinyo, J. M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 (11) : 3192 - 3201
  • [40] LIMITED IMPACT OF ACUTE REJECTION ON GRAFT OUTCOMES IN BELATACEPT-TREATED KIDNEY TRANSPLANT RECIPIENTS (BENEFIT/BENEFIT-EXT)
    Larsen, C.
    Vincenti, F.
    Grinyo, J. M.
    Charpentier, B.
    Di Russo, G. B.
    Garg, P.
    Dong, Y.
    TRANSPLANT INTERNATIONAL, 2009, 22 : 193 - 193
12345